Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 9:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 112 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Motor Vehicle Accident Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Hazard Anticipation Program for Parents of Teen Drivers

NCT06611241
View directory record Official record
Conditions
Motor Vehicle Accident, Interaction, Parent-Offspring
Interventions
Hazard Anticipation Program for Parents of Teen Drivers
Behavioral
Lead sponsor
Elizabeth O'Neal
Other
Eligibility
14 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 7, 2026, 9:58 PM EDT
Completed Phase 1 Interventional

A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer

NCT00485277
View directory record Official record
Conditions
Breast Cancer
Interventions
MVA-BN-HER2
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Berkeley, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 7, 2026, 9:58 PM EDT
Suspended Phase 1Phase 2 Interventional

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

NCT06071767
View directory record Official record
Conditions
HIV-1-infection
Interventions
ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, GS-2872, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 7, 2026, 9:58 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers Results available

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

NCT03560752
View directory record Official record
Conditions
Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Phase CML, BCR-ABL1 Positive, Cytomegalovirus Positive, Donor, Hematopoietic Cell Transplant Recipient, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Myelofibrosis, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 7, 2026, 9:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

NCT04228783
View directory record Official record
Conditions
Ebola
Interventions
Ad26.ZEBOV, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
974 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
7
States / cities
Mobile, Alabama • Tempe, Arizona • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 7, 2026, 9:58 PM EDT
Completed Phase 1 Interventional

CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig

NCT03383055
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma
Interventions
CMV-MVA Triplex Vaccine
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Sep 7, 2026, 9:58 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Effectiveness of Contrast-Enhanced Ultrasound

NCT03473249
View directory record Official record
Conditions
Abdominal Injuries, Physical Abuse, Accidental Fall, Motor Vehicle Injury
Interventions
Contrast-Enhanced Ultrasound using Lumason
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 7 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 7, 2026, 9:58 PM EDT
Completed Phase 1 Interventional

A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy

NCT01152398
View directory record Official record
Conditions
Breast Cancer
Interventions
MVA-BN-HER2
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 7, 2026, 9:58 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer

NCT01191684
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer
Interventions
laboratory biomarker analysis, enzyme-linked immunosorbent assay, flow cytometry, immunoenzyme technique, modified vaccinia virus ankara vaccine expressing p53
Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 7, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

NCT01260727
View directory record Official record
Conditions
HIV Infections
Interventions
PENNVAX-G DNA Vaccine, MVA-CMDR Vaccine, Placebo PENNVAX-G Vaccine, Placebo MVA-CMDR Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 7, 2026, 9:58 PM EDT
Completed Phase 2 Interventional Results available

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

NCT02038881
View directory record Official record
Conditions
Smallpox
Interventions
IMVAMUNE®
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Sep 7, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

NCT02325050
View directory record Official record
Conditions
Healthy
Interventions
MVA-BN-Filo, Ad26. ZEBOV, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 7, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

NCT02743455
View directory record Official record
Conditions
Yellow Fever, Yellow Fever Immunisation
Interventions
ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 7, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults

NCT01571960
View directory record Official record
Conditions
HIV Infections
Interventions
GEO-D03 DNA vaccine, MVA/HIV62B (MVA62B) vaccine, Placebo for GEO-D03 DNA, Placebo for MVA62B:
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Sep 7, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults

NCT00079820
View directory record Official record
Conditions
Smallpox
Interventions
ACAM3000 MVA Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 31 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
2
States / cities
Lenexa, Kansas • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 7, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

NCT02296541
View directory record Official record
Conditions
HIV Infections
Interventions
DNA Nat-B env, DNA CON-S env, DNA Mosaic env, MVA-CMDR, Placebo for DNA Nat-B env, Placebo for DNA CON-S env, Placebo for DNA Mosaic env, Placebo for MVA-CMDR
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Sep 7, 2026, 9:58 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells

NCT07199569
View directory record Official record
Conditions
Monkeypox (Mpox)
Interventions
Jynneos, MVA-BN (Quail)
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 49 Years
Enrollment
970 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
10
States / cities
Ames, Iowa • Lenexa, Kansas • Rochester, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 7, 2026, 9:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mobile Technology Monitoring System to Assess a Web-based Intervention for Teen Risky Driving

NCT02695888
View directory record Official record
Conditions
Adolescent, Accidents, Traffic, Attention, Motor Vehicles
Interventions
Risky Driving Prevention, Teen Healthy Living
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
16 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 7, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox

NCT00053742
View directory record Official record
Conditions
Healthy
Interventions
Modified Vaccinia Virus Ankara TBC-MVA
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 7, 2026, 9:58 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluating the Human Immune Response to the JYNNEOS Vaccine

NCT06366672
View directory record Official record
Conditions
Vaccinia, Virus Diseases
Interventions
JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection, Phlebotomy, Research bronchoscopy, Skin punch biopsy, Bone marrow aspiration
Biological · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 7, 2026, 9:58 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

ACAM 3000 MVA at Harvard Medical School

NCT00133575
View directory record Official record
Conditions
Smallpox
Interventions
MVA Smallpox Vaccine, Placebo, Live vaccinia virus vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 38 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2015 · Synced Sep 7, 2026, 9:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Vitamin D to ENhance TraUma REcovery

NCT05458024
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
Vitamin D 2, Vitamin D2 Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Worcester, Massachusetts • St Louis, Missouri • Camden, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 7, 2026, 9:58 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Randomized Controlled Trial of No Strings Intrauterine Device (IUD) Removal Techniques

NCT05702242
View directory record Official record
Conditions
IUD Threads Not Visible, IUD Removal Complication
Interventions
IUD removal with no visible strings, Alligator forceps, Manual Vacuum Aspirator
Procedure · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 7, 2026, 9:58 PM EDT
Recruiting Phase 1Phase 2 Interventional

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

NCT03354728
View directory record Official record
Conditions
Cytomegaloviral Infection, Hematopoietic Cell Transplant Recipient
Interventions
Laboratory Biomarker Analysis, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
1 Year to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 7, 2026, 9:58 PM EDT